METASTATIC KRAS G12D-MUTATED PANCREATIC ADENOCARCINOMA

Clinical trials for METASTATIC KRAS G12D-MUTATED PANCREATIC ADENOCARCINOMA explained in plain language.

Never miss a new study

Get alerted when new METASTATIC KRAS G12D-MUTATED PANCREATIC ADENOCARCINOMA trials appear

Sign up with your email to follow new studies for METASTATIC KRAS G12D-MUTATED PANCREATIC ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New hope for hard-to-treat pancreatic cancer: targeted drug combo enters phase 3 trial

Disease control Recruiting now

This study tests whether adding an experimental drug called zoldonrasib to standard chemotherapy helps people with a specific genetic form of metastatic pancreatic cancer (KRAS G12D mutation) live longer without their cancer growing. About 670 adults with advanced pancreatic canc…

Matched conditions: METASTATIC KRAS G12D-MUTATED PANCREATIC ADENOCARCINOMA

Phase: PHASE3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control

Last updated Jun 08, 2026 13:04 UTC

METASTATIC KRAS G12D-MUTATED PANCREATIC ADENOCARCINOMA

Get alerted when new METASTATIC KRAS G12D-MUTATED PANCREATIC ADENOCARCINOMA trials appear

New hope for hard-to-treat pancreatic cancer: targeted drug combo enters phase 3 trial